Cargando…
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”
We analyzed BCR::ABL1 expression at stop and in the first month after discontinuation in 168 chronic myeloid leukemia patients who stopped imatinib or 2nd generation tyrosine kinase inhibitors (2G‐TKIs) while in sustained deep molecular response. Patients were divided among those who maintained resp...
Autores principales: | Di Giusto, Sara, Toffoletti, Eleonora, Bonifacio, Massimiliano, Binotto, Gianni, Miggiano, Maria Cristina, Calistri, Elisabetta, Stulle, Manuela, Ermacora, Anna, Stella, Rossella, Scaffidi, Luigi, D'Amore, Fabio, Scotton, Giorgia, Griguolo, Davide, De Matteis, Giovanna, Bertorelle, Roberta, Krampera, Mauro, Semenzato, Gianpietro, Fanin, Renato, Damiani, Daniela, Tiribelli, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939132/ https://www.ncbi.nlm.nih.gov/pubmed/36208021 http://dx.doi.org/10.1002/cam4.5158 |
Ejemplares similares
-
Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)
por: Bonifacio, Massimiliano, et al.
Publicado: (2020) -
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
por: Tiribelli, Mario, et al.
Publicado: (2018) -
The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population
por: Bonifacio, Massimiliano, et al.
Publicado: (2021) -
An x-ray image of the LMC
Publicado: (1994) -
P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
por: Luca Morelli, Gian, et al.
Publicado: (2023)